1/16
Looks like no tags are added yet.
polymorphisms of pharmacodynamic target of Warfarin
VKORC1
CYP4F2
GCCX
pharmacoDYNAMIC targeting: VKORC1
low levels will cause low levels of reduced vitamin K → lower warfarin dose
c. -1693G>A (rs9923231)
pharmacoDYNAMIC targeting: CYP4F2
reduced function will cause high levels of reduced vitamin K → increase warfarin dose
CYP4F2*3/*3
PharmacoKINETIC targeting of Warfarin: CYP2C9
CYP2C9*2/*2, CYP2C9*3/*3
increases levels of warfarin → lower warfarin dose
usually east asians and oceanic
therapeutic plan for warfarin based on pgx test results for VKORC1 and CYP2C9

T or F: PGx replaces INR monitoring
false
most impactful variable on warfarin dose is —
known non-genetic factors
age
sex
race
weight
height
clinical trials on warfarin: COAG
genotype vs clinically guided
ethically diverse
CYP2C9, VKORC1
clinical trials on warfarin: EU-PACT
genotype vs fixed dose
homogenous european population
CYP2C9, VKORC1
clinical trials on warfarin: GIFT
RCT on safety
genotype vs clinically guided
CYP2C9, VKORC1, CYP4F2*3
“Genotype-guided dosing may improve the safety of warfarin initiation among patients undergoing hip or knee arthroplasty”
— is the most commonly used algorithm
warfarindosing.com
CYP2B6*6 & *9
decreased function
most common in AA and oceanian
CYP2B6*18
no function
CYP2B6*4
increased function
Efavirenz
600 mg PO daily (“one pill, once a day” regimen)
decreased activity of CYP2B6 will — active efavirenz concentration
increase concentration → higher risk of CNS toxicity
therapeutic plan for efavirenz based on PGx test results for CYP2B6
